122 related articles for article (PubMed ID: 8996548)
1. Comparison of fluorescent in situ hybridization (FISH) and the polymerase chain reaction (PCR) for detection of residual neuroblastoma cells.
Eckschlager T; McClain K
Neoplasma; 1996; 43(5):301-3. PubMed ID: 8996548
[TBL] [Abstract][Full Text] [Related]
2. [Detection of n-myc gene amplification in neuroblastoma using polymerase chain reaction based methods].
Melegh Z; Bálint I; Nagy K; Magyarosy E; Galántai I; Szentirmay Z
Magy Onkol; 2002; 46(1):43-8. PubMed ID: 12050681
[TBL] [Abstract][Full Text] [Related]
3. Detection of n-myc gene amplification in neuroblastoma by comparative, in situ,and real-time polymerase chain reaction.
Melegh Z; Bálint I; Tóth E; Csernák E; Szentirmay Z; Nagy K
Pediatr Pathol Mol Med; 2003; 22(3):213-22. PubMed ID: 12746172
[TBL] [Abstract][Full Text] [Related]
4. Detection of N-myc amplification by FISH in immature areas of fixed neuroblastomas: more efficient than Southern blot/PCR.
Sartelet H; Grossi L; Pasquier D; Combaret V; Bouvier R; Ranchère D; Plantaz D; Munzer M; Philip T; Birembaut P; Zahm JM; Bergeron C; Gaillard D; Pasquier B
J Pathol; 2002 Sep; 198(1):83-91. PubMed ID: 12210067
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma.
Komada Y; Zhang XL; Zhou YW; Inaba H; Deguchi T; Azuma E; Sakurai M
Cancer; 1998 Feb; 82(3):591-9. PubMed ID: 9452279
[TBL] [Abstract][Full Text] [Related]
6. Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma.
Lambooy LH; Gidding CE; van den Heuvel LP; Hulsbergen-van de Kaa CA; Ligtenberg M; Bökkerink JP; De Abreu RA
Clin Cancer Res; 2003 Feb; 9(2):812-9. PubMed ID: 12576454
[TBL] [Abstract][Full Text] [Related]
7. Rapid detection of MYCN gene amplification in neuroblastomas using the polymerase chain reaction.
Crabbe DC; Peters J; Seeger RC
Diagn Mol Pathol; 1992 Dec; 1(4):229-34. PubMed ID: 1342970
[TBL] [Abstract][Full Text] [Related]
8. Determination of N-myc gene amplification in neuroblastoma by differential polymerase chain reaction.
Gilbert J; Norris MD; Haber M; Kavallaris M; Marshall GM; Stewart BW
Mol Cell Probes; 1993 Jun; 7(3):227-34. PubMed ID: 8366868
[TBL] [Abstract][Full Text] [Related]
9. Detection and treatment of minimal residual disease in high-risk neuroblastoma.
Reynolds CP
Pediatr Transplant; 2004 Jun; 8 Suppl 5():56-66. PubMed ID: 15125707
[TBL] [Abstract][Full Text] [Related]
10. [Competitive polymerase chain reaction: a new method for measuring N-myc amplification].
Tornóczky T; Vass J; Kajtár P; Kardos M; Lendvai G; Varga T; Pajor L
Orv Hetil; 2000 Jan; 141(1):27-30. PubMed ID: 10673855
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a complex genomic alteration on chromosome 2p that leads to four alternatively spliced fusion transcripts in the neuroblastoma cell lines IMR-5, IMR-5/75 and IMR-32.
Oberthuer A; Skowron M; Spitz R; Kahlert Y; Westermann F; Mehler K; Berthold F; Fischer M
Gene; 2005 Dec; 363():41-50. PubMed ID: 16216448
[TBL] [Abstract][Full Text] [Related]
12. Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma.
Cheung IY; Cheung NK
Clin Cancer Res; 1997 May; 3(5):821-6. PubMed ID: 9815755
[TBL] [Abstract][Full Text] [Related]
13. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
[TBL] [Abstract][Full Text] [Related]
14. Amplification and detection of a Y-chromosome DNA sequence by fluorescence in situ polymerase chain reaction and flow cytometry using cells in suspension.
Timm EA; Podniesinski E; Duckett L; Cardott J; Stewart CC
Cytometry; 1995 Sep; 22(3):250-5. PubMed ID: 8556957
[TBL] [Abstract][Full Text] [Related]
15. [Detection of minimal residual disease by means of FISH and PCR methods and its clinical evaluation].
Misawa S; Taniwaki M; Yokota S
Rinsho Ketsueki; 1995 Apr; 36(4):293-8. PubMed ID: 7783332
[TBL] [Abstract][Full Text] [Related]
16. Combined polymerase chain reaction methods to detect c-myc/IgH rearrangement in childhood Burkitt's lymphoma for minimal residual disease analysis.
Busch K; Borkhardt A; Wössmann W; Reiter A; Harbott J
Haematologica; 2004 Jul; 89(7):818-25. PubMed ID: 15257933
[TBL] [Abstract][Full Text] [Related]
17. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
18. Automatic quantification of gene amplification in clinical samples by IQ-FISH.
Narath R; Lörch T; Rudas M; Ambros PF
Cytometry B Clin Cytom; 2004 Jan; 57(1):15-22. PubMed ID: 14696059
[TBL] [Abstract][Full Text] [Related]
19. Automatic detection and genetic profiling of disseminated neuroblastoma cells.
Méhes G; Luegmayr A; Hattinger CM; Lörch T; Ambros IM; Gadner H; Ambros PF
Med Pediatr Oncol; 2001 Jan; 36(1):205-9. PubMed ID: 11464886
[TBL] [Abstract][Full Text] [Related]
20. Duplication of N-MYC at its resident site 2p24 may be a mechanism of activation alternative to amplification in human neuroblastoma cells.
Corvi R; Savelyeva L; Schwab M
Cancer Res; 1995 Aug; 55(16):3471-4. PubMed ID: 7627947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
